702-17-0

Basic information

• Product Name: 2-(4-Fluoro-phenylaMino)-ethanol
• Synonyms: 2-(4-Fluoro-phenylaMino)-ethanol
• CAS NO: 702-17-0
• Molecular Formula: C₈H₁₀FNO
• Molecular Weight: 155.1695032
• Mol File: 702-17-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 145-146 °C(Press: 2 Torr)
• Appearance: /
• Density: 1.220±0.06 g/cm3(Predicted)
• PKA: 14.67±0.10(Predicted)
• CAS DataBase Reference: 2-(4-Fluoro-phenylaMino)-ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Fluoro-phenylaMino)-ethanol(702-17-0)
• EPA Substance Registry System: 2-(4-Fluoro-phenylaMino)-ethanol(702-17-0)

Safety Data

• Hazardous Substances Data: 702-17-0(Hazardous Substances Data)

Usage

Chemical classification

Ethanolamine derivative

Substituent group

Fluorine-substituted phenylamino

Potential use

Pharmaceutical intermediate, building block in organic synthesis

Pharmacological properties

Beta-adrenergic antagonist

Possible applications

Development of new drugs for various medical conditions

Versatility

Potential uses in both pharmaceutical and research fields

Upstream product

• 371-40-4 4-fluoroaniline 
• 540-51-2 2-bromoethanol 
• 107-21-1 ethylene glycol 
• 6096-89-5 2-(4-fluorophenoxy)-1-ethylamine 
• 624-76-0 Iodoethanol 

Downstream Products

• 1609980-51-9 2-{[3-(5-amino-1H-1,2,4-triazol-3-yl)propyl](4-fluorophenyl)amino}ethan-1-ol 
• 1609980-49-5 2-[(3-{5,7-diethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}propyl)(4-fluorophenyl)amino]ethan-1-ol 
• 1609980-52-0 2-[(3-{5,7-diethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}propyl)(4-fluorophenyl)amino]ethyl acetate 
• 1609980-50-8 methyl 4-[(4-fluorophenyl)(2-hydroxyethyl)amino]butanoate 

Relevant articles and documents

NOVEL PHARMACEUTICAL COMPRISING HETEROAROMATIC AMIDE DERIVATIVE OR SALT THEREOF

PROBLEM TO BE SOLVED: To provide a compound useful for treating or preventing disease associated with voltage-dependent sodium channel (Nav1.7) such as disease involving a pain, disease involving an itch, autonomic nerve-associated disease, or a pharmaceutical composition thereof. SOLUTION: The present disclosure provides a compound illustrated by the following formula, and a pharmaceutical composition containing the same. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

β-Amino alcohols from anilines and ethylene glycol through heterogeneous Borrowing Hydrogen reaction

Borrowing Hydrogen (BH), also called Hydrogen Autotransfer (HA), reaction with neat ethylene glycol represents a key step in the preparation of β-amino alcohols. However, due to the stability of ethylene glycol, mono-activation has rarely been achieved. Herein, a combination of Pd/C and ZnO is reported as heterogeneous catalyst for this BH/HA reaction. This system results in an extremely air and moisture stable, and economic catalyst able to mono-functionalize ethylene glycol in water, without further activation of the diol. In this work, different diols and aromatic amines have been explored affording a new approach towards amino alcohols. This study reveals how the combination of two solid species can afford interesting catalytic properties in heterogeneous phase. ZnO activates ethylene glycol while Pd/C is the responsible of the BH/HA cycle. This catalytic system has also been found useful to dehydrogenate indoles affording indolines that undergo in situ BH/HA cycle prior to re-aromatization, representing a tandem heterogeneous process.

SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL

Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.